Relay Therapeutics, Inc. (RLAY) Tops Q3 EPS by 29c

Relay Therapeutics, Inc. (NASDAQ: RLAY) reported Q3 EPS of ($0.54), $0.29 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $25.2 million versus the consensus estimate of $374.55 thousand.

For earnings history and earnings-related data on Relay Therapeutics, Inc. (RLAY) click here.

You May Also Be Interested In

• SanDisk stock target lifted by Citi on continued demand strength
• Rank One Computing (ROC) Reiterated at Buy by Benchmark Post ZTC Acquisition
• BlackBerry (BB) Tops Q1 EPS by 1c, Offers Guidance